Scancell Holdings (LSE:SCLP): Can a Nasdaq deal fund its pivotal melanoma trial?

Scancell Holdings plc (LSE:SCLP) has produced encouraging Phase 2 melanoma data and secured United States Food and Drug Administration Fast Track designation for iSCIB1+, but the value of that clinical progress now depends on financing a global registrational study. The AIM-listed cancer immunotherapy company is in advanced discussions to acquire Nasdaq-listed Neuphoria Therapeutics through an all-share transaction while separately exploring equity and debt funding for the Phase 3 programme. A completed transaction could provide Scancell Holdings with a Nasdaq presence and greater access to specialist United States biotechnology investors, although the terms, dilution and funding package remain unknown. Scancell Holdings shares traded around 13.75 pence on July 10, valuing the company at approximately £142.7 million after falling sharply from their June highs.

What does Scancell Holdings develop and why is its cancer immunotherapy model differentiated?

Scancell Holdings develops off-the-shelf active immunotherapies intended to train a patient’s immune system to recognise and attack cancer cells. Its lead programmes are based on the ImmunoBody and Moditope platforms, while its wholly owned GlyMab Therapeutics subsidiary develops antibodies targeting sugar structures found on cancer cells.

The lead asset, iSCIB1+, is a DNA-based active immunotherapy being developed for advanced unresectable melanoma. It is designed to stimulate tumour-specific T-cell responses and is administered alongside checkpoint inhibitors, medicines that remove biological restraints preventing immune cells from attacking cancer.

The combination strategy is central to the investment case. Checkpoint inhibitors such as nivolumab, ipilimumab and pembrolizumab have transformed melanoma treatment, but a significant proportion of patients either fail to respond or eventually experience disease progression. Scancell Holdings is trying to improve the depth and durability of those responses without materially increasing toxicity.

Unlike personalised cancer vaccines, iSCIB1+ is designed as an off-the-shelf product that can be manufactured in advance and used across patients carrying selected human leukocyte antigen types. The target population represents approximately 80% of melanoma patients, potentially giving the programme broader commercial scalability than therapies requiring individual tumour sequencing and patient-specific manufacturing.

The differentiation remains clinically promising rather than commercially proven. Scancell Holdings must demonstrate in a randomised Phase 3 trial that adding iSCIB1+ produces a statistically and clinically meaningful improvement over checkpoint inhibitor therapy alone. Manufacturing convenience and immune-response data will matter little if the pivotal study fails to confirm the efficacy signal.

What does the latest iSCIB1+ melanoma data really mean for Scancell investors?

The Phase 2 SCOPE study evaluated SCIB1 and iSCIB1+ alongside standard checkpoint inhibitor treatment in patients with advanced unresectable melanoma. The latest iSCIB1+ update reported progression-free survival of 77% at 20 months in the selected target population receiving ipilimumab and nivolumab.

That result compares favourably with the 43% progression-free survival reported at the same point for ipilimumab and nivolumab in historical standard-of-care data. The apparent difference is large enough to justify a registrational programme and contributed to the United States Food and Drug Administration granting Fast Track designation.

However, the comparison is not the same as a randomised head-to-head trial. The SCOPE result comes from an open-label Phase 2 study, while the comparator originates from a separate historical trial conducted in a different patient population and treatment setting. Patient selection, baseline risk, follow-up and other clinical variables can influence outcomes.

The planned Phase 3 trial is therefore the decisive test. It must show that the outcome difference persists when patients are prospectively selected and randomised under a controlled protocol. A smaller benefit than the historical comparison suggests could still be clinically useful, but it may affect commercial pricing, adoption and the attractiveness of the programme to pharmaceutical partners.

More mature progression-free survival and early overall survival data are expected during the first half of 2027. Those results may strengthen or weaken the biological case while the Phase 3 programme is underway, making the existing SCOPE patients an important continuing source of value-sensitive information.

Why could the proposed Neuphoria Therapeutics deal reshape the SCLP investment case?

Scancell Holdings confirmed in June that it was in advanced discussions to acquire Neuphoria Therapeutics through an all-share transaction. The proposed structure could result in Scancell Holdings gaining a Nasdaq listing, subject to final documentation and completion.

The strategic attraction is primarily capital-market access. Late-stage oncology trials require substantial funding, and Nasdaq offers a deeper pool of specialist biotechnology investors than AIM. A United States listing could improve visibility among healthcare funds that understand clinical-stage valuation and are more accustomed to financing pivotal trials.

The transaction does not automatically solve the funding problem. Scancell Holdings is separately discussing possible equity and debt financing for the iSCIB1+ Phase 3 study, indicating that the Nasdaq route and the clinical funding package are connected but not interchangeable.

Investors must wait for the proposed ownership split, share-exchange ratio, board structure, financing commitments and treatment of both companies’ existing assets and liabilities. An all-share structure could preserve cash, but it would dilute current Scancell Holdings shareholders depending on how much of the combined company is issued to Neuphoria Therapeutics investors.

Neuphoria Therapeutics is itself a clinical-stage biotechnology company that began a strategic review after its BNC210 Phase 3 social anxiety disorder programme failed to meet its primary and secondary endpoints. Development in that indication was halted, although Neuphoria Therapeutics retains other neuropsychiatric assets and partnered programmes.

This history makes the transaction more complex than purchasing an empty Nasdaq shell. Scancell Holdings would need to decide which Neuphoria Therapeutics programmes remain strategically relevant, how much capital they require and whether management attention should remain concentrated on iSCIB1+.

The market is therefore likely to judge the transaction through three questions. Does it secure enough money to start and sustain Phase 3? Does the exchange ratio preserve reasonable value for existing Scancell Holdings shareholders? Does the Nasdaq structure improve long-term financing access without burdening the combined company with distracting programmes or liabilities?

What must happen before Scancell Holdings can begin the iSCIB1+ Phase 3 trial?

The regulatory foundation is already partly in place. The United States Food and Drug Administration cleared the Investigational New Drug application for the planned registrational study and later awarded iSCIB1+ Fast Track designation.

Fast Track status allows more frequent regulatory engagement and may support rolling review, priority review or an accelerated pathway if future evidence meets the relevant requirements. It does not reduce the need for a well-designed and adequately powered Phase 3 trial.

The principal remaining requirement is financing. Scancell Holdings must secure enough capital to open sites, manufacture clinical supplies, recruit patients, conduct monitoring, collect data and maintain the programme through the planned readout.

The proposed Neuphoria Therapeutics acquisition could form part of that solution, but Scancell Holdings still needs definitive transaction documents and a committed funding package. Shareholder, regulatory, Nasdaq and AIM processes may also be required depending on the final structure.

The next sequence should therefore include a transaction update, financing terms, confirmation of the Phase 3 budget and formal study initiation. The company previously anticipated beginning the registrational trial during the second half of 2026, which leaves a narrowing window for the commercial and financing arrangements to be completed.

A trial-start announcement would be meaningful, but investors should also examine how much of the programme is funded. Raising enough cash to recruit the first patients is different from financing the study through completion. An underfunded launch could leave the company returning to shareholders or lenders before the most important data become available.

Can Modi-1 and GlyMab Therapeutics reduce Scancell’s dependence on one melanoma programme?

Modi-1 is the lead therapy from Scancell Holdings’ Moditope platform. It targets citrullinated peptides, tumour-specific markers generated when cancer cells experience biological stress, and is designed to activate CD4 T cells against those targets.

The Phase 2 ModiFY study is evaluating Modi-1 with checkpoint inhibitors in squamous cell carcinoma of the head and neck and renal cell carcinoma. Earlier head and neck data passed the first-stage non-futility threshold, with three partial responses among seven evaluable patients at the relevant assessment point.

Scancell Holdings had scheduled additional head and neck and renal cell carcinoma data for the first half of 2026. Investors are still awaiting a substantive update on those readouts, creating a secondary catalyst but also a timing question.

Modi-1 could become a meaningful second clinical platform if the larger datasets confirm the early signal. It could also increase partnering flexibility because its mechanism, tumour targets and development pathway differ from those of iSCIB1+.

GlyMab Therapeutics provides a separate antibody opportunity. The platform identifies antibodies that bind to tumour-associated glycan targets, and two programmes, SC129 and SC2811, have already been licensed to Genmab.

The two Genmab agreements have generated upfront revenue and carry the possibility of future development and commercial milestone payments. Those payments could provide non-dilutive funding, although they depend on Genmab advancing the programmes through confidential development plans that Scancell Holdings does not control.

Scancell Holdings is also progressing wholly owned GlyMab candidates, including SC134, which is being prepared for possible clinical development in small-cell lung cancer. These assets broaden the portfolio, but each additional programme competes for capital and management attention while iSCIB1+ approaches its most expensive development stage.

Does Scancell Holdings have enough cash to finance its current clinical ambitions?

Scancell Holdings reported cash of £8.6 million at October 31, 2025, down from £16.9 million six months earlier. It subsequently received approximately £3 million of research and development tax credits in December 2025.

Cash used in operations was £7.2 million during the six-month reporting period. That rate reflects ongoing clinical studies, manufacturing, regulatory work and company overheads, although future expenditure could rise significantly once the global Phase 3 programme begins.

The company also had £18.2 million of convertible loan notes outstanding at the reporting date. Of that amount, £1.75 million is due in August 2027 and £16.45 million is due in November 2027 unless the notes are converted into Scancell Holdings shares.

The notes create a second financing deadline beyond the Phase 3 requirement. A higher share price could make conversion more likely, while a lower price may leave the company needing to refinance or repay the obligations. Either route affects the future capital structure.

Scancell Holdings generated £4.7 million of revenue during FY2025 through its antibody collaboration arrangements, but it recorded no revenue during the first half of FY2026. The company remains dependent on external financing, licensing receipts and potential milestones rather than recurring product sales.

The proposed Nasdaq transaction may therefore be attempting to solve several problems together. It could broaden the investor base, help finance Phase 3 and create a public-market structure better suited to raising larger amounts of clinical capital.

However, combining a transaction, equity financing, potential debt and existing convertible notes could produce a complicated balance sheet. Retail investors should focus on fully diluted ownership and future financing obligations rather than judging the deal solely by the amount of headline cash raised.

Is the Scancell share price reflecting clinical risk or disappointment over the Nasdaq strategy?

Scancell Holdings traded around 13.75 pence on July 10, giving the company a market capitalisation of approximately £142.7 million. The shares were down about 3.5% over five trading days and approximately 32.9% over one month.

That decline followed a period in which the stock reached a 52-week high of 29.50 pence. The shares remain above the annual low of 7.86 pence, showing that the market continues to assign substantial value to the iSCIB1+ data and broader pipeline.

The recent weakness suggests investors are questioning how the Phase 3 study will be financed and what the Neuphoria Therapeutics transaction could mean for existing ownership. The market has moved from valuing the clinical signal to pricing the cost of proving it.

At roughly £143 million, Scancell Holdings is valued well above many early-stage AIM biotechnology companies. That premium reflects the maturity of iSCIB1+, the regulatory progress, the durability of the SCOPE data and commercial validation from the Genmab agreements.

The valuation remains modest compared with the potential value of an approved first-line melanoma therapy. However, comparing an AIM market capitalisation directly with possible peak pharmaceutical sales ignores Phase 3 failure risk, development costs, future dilution, partner economics and the time required to reach commercialisation.

Visible external research valuations remain materially above the current share price, but coverage is limited and heavily dependent on assumptions about Phase 3 success. A probability-adjusted model can change dramatically when trial costs, launch timing or the assumed probability of approval are revised.

The present price therefore reflects neither outright rejection nor full confidence. It reflects a company with promising clinical data facing a capital-intensive transition where transaction terms may matter almost as much as the science.

Why are retail investors divided over Scancell Holdings after the latest clinical progress?

Scancell Holdings has developed a persistent retail following because the investment thesis combines understandable cancer biology with potentially large commercial outcomes. The reported progression-free survival gap attracts attention because it appears substantially better than historical checkpoint inhibitor results.

Supportive investors believe iSCIB1+ could extend the commercial life and improve the effectiveness of major checkpoint inhibitor franchises. They also view the Nasdaq strategy as evidence that Scancell Holdings is preparing for a larger international development and financing phase.

More cautious investors point to the limitations of historical comparisons and the absence of randomised Phase 3 evidence. They also question why the share price weakened after the Neuphoria Therapeutics discussions became public if the transaction is expected to improve access to capital.

The proposed all-share structure has intensified dilution debate. Some investors see Nasdaq access as worth surrendering part of their ownership, while others want evidence that Neuphoria Therapeutics contributes enough cash, assets or strategic value to justify the shares it may receive.

The delayed visibility around Modi-1 data adds another layer. A positive readout could remind the market that Scancell Holdings is not solely dependent on iSCIB1+, while a disappointing or further delayed update could increase concentration risk.

The most useful retail-investor roadmap now centres on observable events rather than speculative takeover or partnership valuations. These include definitive Neuphoria Therapeutics terms, committed Phase 3 funding, first patient dosing, the outstanding Modi-1 readout, Genmab milestones and updated SCOPE survival data.

Scancell Holdings has already shown enough clinical promise to justify serious attention. The next stage is less forgiving because the company must demonstrate that it can finance, organise and execute a global pivotal trial without allowing capital-structure complexity to consume too much of the value created by the science.

What are the key takeaways for investors watching Scancell Holdings and SCLP?

• iSCIB1+ has produced encouraging Phase 2 melanoma data, including reported progression-free survival of 77% at 20 months in the selected target population.
• The result remains based on an open-label study and historical comparison, making the planned randomised Phase 3 trial the decisive clinical test.
• United States Food and Drug Administration Fast Track designation strengthens regulatory access but does not remove development, funding or approval risk.
• The proposed all-share acquisition of Neuphoria Therapeutics could provide a Nasdaq route, although the exchange ratio, dilution and final financing package remain unknown.
• Scancell Holdings must secure enough capital to fund the Phase 3 programme through meaningful data, not merely finance trial initiation.
• Modi-1 and the Genmab-partnered GlyMab programmes provide secondary catalysts, but their timing and economic contribution remain uncertain.
• The share-price decline from June levels shows that investors are increasingly pricing financing and transaction risk alongside the clinical opportunity.